Roche Bobois S.A.
RBO.PA News Today: Stay Updated with the Latest Roche Bobois S.A. News in Real Time
Find RBO.PA news now at Meyka AI. Stay informed with the latest Roche Bobois S.A. stocks updates, including price news, market analysis, and expert insights.
MLFDV.PA volume spike on EURONEXT €0.40 intraday 02 Apr 2026: assess liquidity
Intraday volume spike for MLFDV.PA stock at €0.40 on EURONEXT; quick liquidity and outlook
Biogen to Buy Apellis in $5.6 Billion All‑Cash Deal
Biotech giant Biogen announced a major deal to acquire Apellis Pharmaceuticals for $5.6 billion in cash, marking one of the largest strategic transactions in the sector this year. The acquisition is aimed at strengthening Biogen’s drug pipeline, especially in areas such as eye disease and immunology where Apellis has developed promising therapies. Investors reacted strongly…
IDIA.SW Idorsia Ltd (SIX) CHF3.08 pre-market 21 Mar 2026: most active, B+ outlook
Pre-market: IDIA.SW stock at CHF3.08 on 21 Mar 2026, high volume 1.98M; Meyka AI gives B+ and model shows upside
BAYN.SW Bayer AG (SIX) up 10.32% pre-market 17 Mar 2026: check key drivers
Pre-market BAYN.SW stock jumps 10.32% to CHF36.13; analysis, grade and Meyka AI forecast included
MMTX.SW +8.98% pre-market on SIX: MindMaze Therapeutics CHF 0.48, catalysts
Pre-market: MMTX.SW stock rises 8.98% to CHF 0.48 on SIX; volume up and Meyka AI forecast and grade included
ROG.SW Roche Holding AG SIX pre-market CHF335.20 most active 11 Mar 2026: Volume rise signals earnings focus
ROG.SW stock pre-market update: CHF335.20, high volume, PE 20.90, Meyka AI monthly forecast CHF348.23
NOVN.SW Novartis AG SIX after hours CHF122.00 (-1.02%) 10 Mar 2026: Earnings focus
NOVN.SW stock at CHF122.00 after hours on SIX; quick analysis of valuation, volume and Meyka AI forecast
SMI Index March 10: Oil Spike Cools as Swiss Stocks Trim Losses
SMI Index pares early losses as Brent oil pulls back near $100. Swiss stock market down about 0.7% after brief 3% slide. Luxury and healthcare lag; oil, G7 moves, and Iran tensions steer CH risk.
LLY.SW Eli Lilly (SIX) -11.11% on 09 Mar 2026: valuation re-rate may deepen
LLY.SW stock falls 11.11% to CHF800.00 on 09 Mar 2026. Meyka AI grade B+ and CHF974.73 year forecast with 21.84% upside